Abbott Laboratories (ABT) receives high rating based on Peter Lynch's P/E/Growth Investor model

From Nasdaq: 2025-07-02 12:04:00

Abbott Laboratories (ABT) has been rated highly by Validea’s guru fundamental report, particularly by Peter Lynch’s P/E/Growth Investor model. With a rating of 87%, ABT is considered a large-cap growth stock in the Medical Equipment & Supplies industry. The stock meets several criteria set by the strategy, including a strong balance sheet and reasonable price relative to earnings growth. Peter Lynch, known for his common sense approach to investing, achieved impressive returns during his time managing Fidelity Investment’s Magellan Fund. Validea follows the strategies of investment legends like Lynch to provide stock analysis and model portfolios for investors.



Read more at Nasdaq: ABT Factor-Based Stock Analysis – Peter Lynch